Preparation method and application of injectable bone adhesive

The existing bone adhesive with high mechanical strength and good adhesion properties is solved by using a combination of aminolated polyhydroxypegylated polysebacterium glycol and phosphorylated polyglutamic acid and tetracalcium phosphate. The problem of insufficient mechanical and adhesion strength of bone adhesives has achieved effective fixation of comminuted fractures and new bone regeneration.

CN119015473APending Publication Date: 2024-11-26EAST CHINA UNIV OF SCI & TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411112902.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing bone adhesives have shortcomings in mechanical and adhesion strength, which is difficult to meet the requirements of reduction and fixation of comminuted fractures. At the same time, injectable performance is required to reduce damage to bone growth.

Method used

Aminated polyhydroxypegylated polyseparate glyceride (PEGS-NH2) and phosphorylated polyglutamic acid (PGA-P) are used as the main matrix materials, tetracalcium phosphate is added, cross-linked and electrostatic by amide bonds Physical crosslinking forms bone adhesives with high mechanical strength and good adhesion properties.

Benefits of technology

It has achieved high mechanical strength, excellent elasticity and toughness, and has good injectable performance and the effect of promoting new bone regeneration. It is suitable for the adhesion of bone fragments in fracture repair surgery to meet the needs of clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004992799570000021
    Figure BDA0004992799570000021
  • Figure BDA0004992799570000022
    Figure BDA0004992799570000022
  • Figure BDA0004992799570000081
    Figure BDA0004992799570000081
Patent Text Reader

Abstract

The invention relates to the field of material science and medicine, in particular to a preparation method and application of an injectable bone adhesive. The injectable bone adhesive provided by the invention comprises the following components: (c1) an organic component, wherein the organic component comprises a first polymer and a second polymer; and (c2) an inorganic component, wherein the inorganic component comprises a calcium phosphate salt and a derivative thereof. The injectable bone adhesive has excellent bone adhesion strength and good mechanical properties, can be highly attached to bone fragments in complex shapes in comminuted fractures, and ensures stable fixation of the bone fragments in fracture repair; meanwhile, the bone adhesive has a certain osteogenic capacity, promotes fracture healing, and is a material which has clinical application prospects and value and is used for bonding bone fragments in fracture treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the fields of material science and medicine, and in particular to a preparation method of an injectable bone adhesive and application thereof. Background Art

[0002] The incidence of fractures, especially comminuted fractures, is increasing year by year worldwide, endangering the health and lives of tens of millions of people. Reduction and fixation of bone fragments are important methods and procedures for the treatment of comminuted fractures. Currently, metal instruments are mostly used for internal fixation in clinical practice, but there are prominent problems such as high cost, unsuitability for comminuted fractures, and the need for secondary surgery. Bone adhesive is a potential alternative product at present. It can achieve rapid and firm fixation of the fracture site through its adhesion to the bone surface and the cohesion of the material itself. It has the advantages of ease of use, safety, and low cost. However, the bone adhesives reported so far generally have the defects of insufficient mechanical and adhesion strength. At the same time, the current clinical surgery for fractures takes minimally invasive surgery as the golden standard to reduce the damage to the normal physiological environment of bone growth, so it is necessary to ensure the injectability of bone adhesives.

[0003] Therefore, in response to the clinical needs in fracture repair surgery, developing an injectable bone adhesive with high mechanical and adhesion strength and a certain osteogenesis effect has very important research significance and application value. Summary of the invention

[0004] The purpose of the present invention is to provide an injectable bone adhesive having high mechanical and adhesive strength and a certain osteogenesis effect, and specifically to design a preparation method and application of the injectable bone adhesive.

[0005] In a first aspect of the present invention, an injectable bone adhesive is provided, the injectable bone adhesive comprising the following components:

[0006] (c1) an organic component, the organic component comprising: a first polymer and a second polymer;

[0007] (c2) Inorganic components, which include calcium phosphate salts and their derivatives.

[0008] In another preferred embodiment, the first polymer is a modified polyester polymer, including: amino polyhydroxy polyethylene glycol polysebacic acid glyceryl ester PEGS-NH2, amino polysebacic acid glyceryl ester, and amino polyethylene glycol polysebacic acid glyceryl ester.

[0009] In another preferred embodiment, the structural unit of the amino polyhydroxy polyethylene glycol polyglycerol sebacate PEGS-NH2 is as shown in Formula I:

[0010]

[0011] Wherein, in Formula I, m1 is an integer of 1-20, and n1 is an integer of 10-80;

[0012] Each X is independently selected from the group consisting of: H, -CO(CH2) t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2, and each structural unit contains 0.5-2 -CO(CH2) on average t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2; wherein t is 1-6.

[0013] In another preferred embodiment, the first polymer has one or more of the following characteristics:

[0014] (a) a number average molecular weight of 5000-100000 Da, preferably 8000-30000 Da, more preferably 8000-18000 Da, and most preferably 8000-15000 Da;

[0015] (b) the molecular weight distribution coefficient is 1.0 to 2.0, preferably 1.0 to 1.5;

[0016] (c) In one structural unit, it contains at least 0.5 -CO(CH2) on average t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2, preferably containing at least one -CO(CH2) t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2; wherein t is 1-6.

[0017] In another preferred embodiment, in one structural unit, at least 1.8 -CO(CH2) are contained on average t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2; wherein t is 1-6.

[0018] In another preferred embodiment, the second polymer is a polyamino acid or a phosphorylated modified product thereof, including: polyglutamic acid, phosphorylated polyglutamic acid PGA-P, polyaspartic acid, and phosphorylated polyaspartic acid.

[0019] In another preferred embodiment, the structural unit of the phosphorylated polyglutamic acid PGA-P is shown in Formula II:

[0020]

[0021] Wherein, in formula II, n2 is an integer of 100-2000;

[0022] Each Y is independently -OH, -OOP(OH)2, -NH(CH2) t OOP(OH)2 or -NH(CH2) t C(OH)(H2PO3)2, and each structural unit contains an average of 0.5-1 -OOP(OH)2, -NH(CH2) t OOP(OH)2 or -NH(CH2) t C(OH)(H2PO3)2; wherein t is 1-4.

[0023] In another preferred embodiment, the second polymer has one or more of the following characteristics:

[0024] (a) a number average molecular weight of 10-1000 kDa, preferably 10-300 kDa;

[0025] (b) the molecular weight distribution coefficient is 1.0 to 2.0, preferably 1.0 to 1.5;

[0026] (c) In one structural unit, an average of at least 0.3 -OOP(OH)2, -NH(CH2)tOOP(OH)2 or -NH(CH2)tC(OH)(H2PO3)2 is contained, and preferably at least 0.5 -OOP(OH)2, -NH(CH2)tOOP(OH)2 or -NH(CH2)tC(OH)(H2PO3)2 is contained; wherein t is 1-4.

[0027] In another preferred embodiment, in one structural unit, at least 0.7 -OOP(OH)2, -NH(CH2) t OOP(OH)2 or -NH(CH2) t C(OH)(H2PO3)2; wherein t is 1-4.

[0028] In another preferred embodiment, the mass ratio of the first polymer to the second polymer in the organic component is 2:1-1:3.

[0029] In another preferred embodiment, the mass ratio of the first polymer to the second polymer in the organic component is 1.5:1-1:3.

[0030] In another preferred embodiment, the calcium phosphate salt and its derivatives are selected from one or a mixture of two or more of hydroxyapatite, tetracalcium phosphate, tricalcium phosphate, octacalcium phosphate and monocalcium phosphate.

[0031] In another preferred embodiment, the mass ratio of the organic component to the inorganic component is 1:1-4:1.

[0032] In another preferred embodiment, the mass ratio of the organic component to the inorganic component is 1:1-3:1, preferably 1:1 to 2:1.

[0033] In another preferred embodiment, the injectable bone adhesive has one or more of the following characteristics:

[0034] (1) High mechanical strength, compression modulus reaches 600-1200 kPa, preferably 800-1000 kPa, compression strength reaches 400-700 kPa, more preferably 600-700 kPa;

[0035] (2) Excellent elasticity and toughness, the material toughness reaches 0.1-0.2MJ·m -3 , and the better one is 0.13-0.17MJ·m -3 ;

[0036] (3) Good injectability, gelation time is 0.3-1min;

[0037] (4) It can be injected in situ into the gaps between bone fragments, solidify quickly and adhere strongly to bone tissue.

[0038] In a second aspect of the present invention, there is provided a method for preparing the injectable bone adhesive as described in the first aspect, the method comprising the steps of:

[0039] (a) providing a bone adhesive precursor solution, wherein the bone adhesive precursor solution comprises a first polymer, a second polymer, and a calcium phosphate salt;

[0040] (b) providing a cross-linking agent solution, wherein the cross-linking agent comprises 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS);

[0041] (c) mixing the bone adhesive precursor solution with the cross-linking agent solution to obtain the injectable bone adhesive,

[0042] The preparation of the bone adhesive precursor solution comprises the following steps:

[0043] (a1) dissolving the first polymer and the second polymer in a solvent to obtain a mixed solution;

[0044] (a2) adding calcium phosphate salt to the mixed solution, and mixing to obtain the bone adhesive precursor solution.

[0045] In another preferred embodiment, the first polymer and the second polymer are cross-linked via an amide bond.

[0046] In another preferred embodiment, the step (c) comprises: transferring the mixture of the bone adhesive precursor solution and the cross-linking agent solution into a syringe, and injecting the mixture to form the bone adhesive.

[0047] In another preferred embodiment, the cross-linking agent in step (b) is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) for catalyzing the formation of amide bonds.

[0048] In another preferred embodiment, the molar ratio of EDC to NHS in the cross-linking agent in step (b) is 0.5-2:1, and the molar ratio of EDC to the amino group in the first polymer is 0.5-1:1.

[0049] In another preferred embodiment, the solvent in step (a1) is selected from the following group: ultrapure water, PBS solution (pH=7.2), or a combination thereof.

[0050] In another preferred embodiment, the viscosity of the bone adhesive precursor solution is 80-120 mPa·s.

[0051] In another preferred embodiment, the molar ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to N-hydroxysuccinimide is 0.5-2:1, preferably 0.8-1.2:1, and more preferably 1:1.

[0052] In another preferred embodiment, the concentration of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in the cross-linking agent is 0.2 to 0.7 g / mL.

[0053] In another preferred embodiment, the viscosity of the cross-linking agent solution is 0.6-0.8 mPa·s.

[0054] In another preferred embodiment, the injectable bone adhesive has excellent mechanical properties and bone tissue adhesion properties.

[0055] In another preferred embodiment, the method for preparing the first polymer comprises the following steps:

[0056] (a1) adding sebacic acid and tetrabutylammonium hydroxide into anhydrous ethanol in a molar ratio of 1:2-8, and stirring to react to obtain a white product;

[0057] (b1) under a nitrogen atmosphere, dissolving sebacic acid, polyethylene glycol diglycidyl ether (PEGDGE) and the white product obtained in step (a1) in anhydrous N,N-dimethylformamide at a molar ratio of 1:0.8-1.2:0.003-0.009, and stirring the mixture at 90-120° C. for 60-96 h to obtain a first mixture;

[0058] (c1) dialyzing the first mixture obtained in the purification step (b1) to obtain purified polyethylene glycol-polysebacic acid glyceride;

[0059] (d1) under nitrogen atmosphere, the purified polyethylene glycol-polysebacic acid glyceride (calculated by hydroxyl group) obtained in step (c1), amination reagent, N,N'-diisopropylcarbodiimide (DIC) and 4-dimethylaminopyridine (DMAP) were dissolved in anhydrous dichloromethane at a molar ratio of 1:1-1.4:1.5-2.5:0.02-0.07, and the mixture was stirred at room temperature for 20-30 hours to obtain a second mixture;

[0060] (e1) The second mixture obtained in step (d1) is filtered, concentrated, and then the tert-butyloxycarbonyl group is removed with trifluoroacetic acid, followed by purification by dialysis to obtain the first polymer.

[0061] The amination agent is selected from the group consisting of N-(tert-butyloxycarbonyl)aminoacetic acid (BOC-glycine), N-(tert-butyloxycarbonyl)aminovaleric acid, hydrazideacetic acid and guanidinoacetic acid.

[0062] In another preferred embodiment, the preparation method of the second polymer comprises the following steps:

[0063] (a2) dissolving polyamino acid, phosphorylation reagent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) in ultrapure water at a molar ratio of 1:0.8-1.2:1.2-1.8:1.2-1.8, stirring at room temperature for 20-30 hours to obtain a colorless transparent liquid;

[0064] (b2) Dialysis purification step (a2) to obtain a colorless transparent liquid, and freeze-drying to obtain the second polymer.

[0065] In another preferred embodiment, the polyamino acid is a polyamino acid having a pendant carboxyl group.

[0066] In another preferred embodiment, the polyamino acid is selected from the group consisting of polyglutamic acid, polyaspartic acid, and some short peptides.

[0067] In another preferred embodiment, the short peptide is such as glutathione or RGD short peptide.

[0068] In another preferred embodiment, the phosphorylation agent is selected from the following group: O-phosphoethanolamine, pamidronate, and alendronate.

[0069] In another preferred embodiment, the mass ratio of the first polymer to the second polymer is 2:1 to 1:3, preferably 1:1 to 1:2, and more preferably 1:1 to 1:1.5.

[0070] In another preferred embodiment, in step (a1), the concentration of the first polymer is 20-50%, and the concentration of the second polymer is 40-70%, calculated as solute (g) / solvent (mL) mass volume percentage.

[0071] In a third aspect of the present invention, a kit for forming the injectable bone adhesive according to the first aspect is provided, the kit comprising: the bone adhesive precursor solution according to the first aspect and a cross-linking agent solution.

[0072] In another preferred embodiment, the bone adhesive precursor solution and the cross-linking agent solution are mixed to form a mixture, wherein the initial viscosity of the mixture is 80-120 mPa·s, meeting the requirement of injectability.

[0073] In another preferred embodiment, the mixture is injected into the bone tissue site to be bonded, and cross-linked in situ to obtain the bone adhesive described in the first aspect of the present invention.

[0074] In another preferred embodiment, the gelling time of the mixture is 0.3-1 minute.

[0075] In a fourth aspect of the present invention, there is provided a use of the injectable bone adhesive as described in the first aspect, for any one or two or more of the following applications:

[0076] (i) preparing bone fragment bonding materials for fracture repair surgery;

[0077] (ii) preparing bone tissue defect filling materials;

[0078] (iii) preparing materials for guiding tissue regeneration;

[0079] (iv) Preparation of medical cosmetic materials.

[0080] In another preferred embodiment, a medical glue is provided, wherein the medical glue comprises the injectable bone adhesive described in the first aspect.

[0081] In another preferred embodiment, a medical material is provided, wherein the medical material includes the injectable bone adhesive described in the first aspect.

[0082] In another preferred embodiment, the medical material is selected from the following group: medical bone tissue adhesive, medical tooth tissue adhesive, medical adhesive, medical bone repair material, medical tooth repair material.

[0083] In another preferred embodiment, a method for filling bone tissue defects and / or guiding bone tissue regeneration is provided, the method comprising applying the injectable bone adhesive described in the first aspect to a site to be treated.

[0084] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0085] Figure 1 A schematic diagram showing the structure and application of the bone adhesive material of the present invention.

[0086] Figure 2 The hydrogen nuclear magnetic resonance spectrum (A) and the Fourier transform infrared spectrum (B) of the amino-polyethylene glycol polysebacic acid glyceryl ester in the present invention are shown.

[0087] Figure 3 The nuclear magnetic resonance hydrogen spectrum (A), the nuclear magnetic resonance phosphorus spectrum (B), and the Fourier transform infrared spectrum (C) of the phosphorylated polyglutamic acid in the present invention are shown.

[0088] Figure 4 The injectability of the injectable bone adhesive of the present invention is shown.

[0089] Figure 5 A time-sweep rheological curve of the injectable bone adhesive of the present invention is shown.

[0090] Figure 6 The effects of different formulations on the wet environment bonding properties of injectable bone cements are shown. The effects of different organic-inorganic ratios on the bonding strength of injectable bone cements (A); the effects of different ratios of the first polymer and the second polymer in the organic component on the bonding strength of injectable bone cements (B). Figure 7 The wet environment bonding curve graph (A) and bonding strength graph (B) of the injectable bone adhesive of the present invention at different crosslinking degrees are shown. The p value is a numerical value indicating the level of significant difference and when its value is less than 0.05, it indicates that the two groups of data have significant differences, among which *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0091] Figure 8The wet environment compressive stress-strain curve of the injectable bone adhesive of the present invention is shown (A); the compression modulus graph (B); and the compression strength graph (C). The p value is a numerical value indicating the level of significant difference and when its value is less than 0.05, it indicates that the two groups of data have significant differences, where *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0092] Fig. 9 The wet environment cyclic loading compressive stress-strain curve (A) and energy loss diagram (B) of the injectable bone adhesive of the present invention are shown. The p value is a numerical value indicating the level of significant difference and when its value is less than 0.05, it indicates that the two groups of data have significant differences, among which *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0093] Fig.10 The swelling and mechanical properties of different groups of adhesives in the present invention are compared. It can show the presence or absence of chemical crosslinking, the presence or absence of calcium phosphate salt reinforcement, and the comparison of the electrostatic interaction between the phosphate group and the carboxyl group. Actual picture of different groups after swelling for 24 hours (A); Swelling rate of different groups after swelling for 24 hours (B); Compression modulus of different groups after swelling for 24 hours (C); Compression strength of different groups after swelling for 24 hours (D). The p value is a numerical value indicating the level of significant difference and when its value is less than 0.05, it indicates that the two groups of data have significant differences, where *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0094] Fig.11 The cell safety of the injectable bone adhesive of the present invention is shown. The p value is a numerical value indicating the level of significant difference and when its value is less than 0.05, it indicates that the two groups of data have significant differences, among which *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0095] Fig.12 The graph shows the osteogenic differentiation-promoting performance of the injectable bone adhesive of the present invention on mesenchymal stem cells.

[0096] Fig.13 The CT images of the tibial fracture fragments bonded and repaired with the injectable bone adhesive of the present invention at 4 and 8 weeks are shown. DETAILED DESCRIPTION

[0097] The inventors have conducted extensive and in-depth research and, through a large number of experimental screenings, unexpectedly developed for the first time an injectable bone adhesive with high mechanical and adhesive strength and the ability to promote new bone regeneration, which is used for the bonding of bone fragments in fracture repair surgery. In the present invention, amino polyhydroxy polyethylene glycol polysebacic acid glyceride (PEGS-NH2) and phosphorylated polyglutamic acid (PGA-P) are used as the main matrix materials, tetracalcium phosphate (TTCP) is added, and a bone adhesive precursor solution with a certain viscosity is formed through the electrostatic action of the phosphate group and the carboxyl group on the calcium ion. Finally, under the action of the cross-linking agent EDC / NHS, the above-mentioned bone adhesive precursor solution can be mixed and injected into the surface of the bone tissue, and is quickly cured in situ and forms a strong bonding effect.

[0098] The injectable bone adhesive of the present invention has a double cross-linked network inside, including PEGS-NH2 and PGA-P in the organic component forming covalent chemical cross-linking under the action of a cross-linking agent, and electrostatic physical cross-linking spontaneously formed by PGA-P and inorganic calcium phosphate. At the same time, the injectable bone adhesive of the present invention can form a variety of bonds with the surface of bone tissue, including stable amide covalent bonds, electrostatic complexation and hydrogen bonding of phosphate groups and carboxyl groups to calcium ions. The introduction of calcium phosphate components not only improves the mechanical properties of the bone adhesive, but also enhances its osteoconductivity, promotes new bone regeneration, and is beneficial to fracture recovery. In addition, it has good injectability, can be injected into the surface of bone tissue to solidify into gel in situ and form a strong adhesion effect. Therefore, the injectable bone adhesive of the present invention can be used for the bonding of bone fragments in fracture repair surgery, and has clinical application prospects. The hydrogel of the present invention has excellent mechanical properties and performance of promoting osteogenesis. The present invention has been completed on this basis.

[0099] Terminology

[0100] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0101] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0102] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0103] As used herein, the term "bone adhesive precursor solution" refers to a uniform dispersion formed by dissolving components forming a bone adhesive (including but not limited to a first polymer, a second polymer and a calcium phosphate salt) in a specific solvent.

[0104] As used herein, the term "crosslinking agent" refers to a component that can crosslink the components in the bone adhesive precursor solution to form a bone adhesive having a spatial three-dimensional structure.

[0105] As used herein, the term "dispersion coefficient" refers to the ratio of weight average molecular weight to number average molecular weight for long-chain polymers, D = Mw / Mn, D ≥ 1. Due to the polydispersity of polymers, the mass has a non-uniform nature, and the dispersion coefficient is used to characterize the mass distribution of polymer products. The closer it is to 1, the more uniform the mass distribution is.

[0106] As used herein, the terms "amino-polyhydroxy polyethylene glycol-polyglyceryl sebacate", "amino-PEGS", and "PEGS-NH2" are used interchangeably.

[0107] As used herein, the terms "phosphorylated polyglutamic acid," "PGA-P," are used interchangeably.

[0108] As used herein, the terms "1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride," "EDC," are used interchangeably.

[0109] As used herein, the terms "N-hydroxysuccinimide," "NHS," are used interchangeably.

[0110] As used herein, the terms "phosphate buffered saline," "PBS," are used interchangeably.

[0111] As used herein, the terms "di(tetrabutylammonium hydroxide) sebacate," "TBAS," are used interchangeably.

[0112] As used herein, the terms "polyethylene glycol diglycidyl ether," "PEGDGE," are used interchangeably.

[0113] As used herein, the terms "N-(tert-butyloxycarbonyl)aminoacetic acid", "BOC-glycine" are used interchangeably.

[0114] As used herein, the terms "N,N'-diisopropylcarbodiimide," "DIC," are used interchangeably.

[0115] As used herein, the terms "4-dimethylaminopyridine," "DMAP," are used interchangeably.

[0116] As used herein, in the terms "NPC4", "NPC5", "NPC6" and "NPC7", N represents PEGS-NH2, P represents PGA-P, C represents calcium phosphate, and 4, 5, 6, and 7 refer to the degree of cross-linking of the injectable bone adhesive.

[0117] Injectable bone adhesive of the present invention

[0118] The bone adhesive of the present invention is an organic-inorganic composite structure composed of bionic bone, wherein the organic component includes a first polymer and a second polymer, and the inorganic component includes calcium phosphate and its derivatives. The bone adhesive is prepared by cross-linking the first polymer and the second polymer and compounding calcium phosphate.

[0119] Specifically, the first polymer is a modified polyester polymer, including: amino polyhydroxy polyethylene glycol polysebacic acid glyceryl ester PEGS-NH2, amino polysebacic acid glyceryl ester, and amino polyethylene glycol polysebacic acid glyceryl ester.

[0120] In a preferred embodiment of the present invention, the structural unit of the amino polyhydroxy polyethylene glycol polyglycerol sebacate PEGS-NH2 is as shown in Formula I:

[0121]

[0122] Wherein, in Formula I, m1 is an integer of 1-20, and n1 is an integer of 10-80;

[0123] Each X is independently selected from the group consisting of: H, -CO(CH2) t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2, and each structural unit contains 0.5-2 -CO(CH2) on average t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2; wherein t is 1-6.

[0124] Preferably, the first polymer has one or more of the following characteristics:

[0125] (a) a number average molecular weight of 5000-100000 Da, preferably 8000-30000 Da, more preferably 8000-18000 Da, and most preferably 8000-15000 Da;

[0126] (b) the molecular weight distribution coefficient is 1.0 to 2.0, preferably 1.0 to 1.5;

[0127] (c) In one structural unit, it contains at least 0.5 -CO(CH2) on average t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2, preferably containing at least one -CO(CH2) t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2; wherein t is 1-6.

[0128] Preferably, in one structural unit, at least 1.8 -CO(CH2) are contained on average t NH2, -CO(CH2) t CONHNH2 or -CO(CH2) t NHC(=NH)NH2; wherein t is 1-6.

[0129] In a preferred embodiment of the present invention, the second polymer is a polyamino acid or a phosphorylated modified product thereof, including: polyglutamic acid, phosphorylated polyglutamic acid PGA-P, polyaspartic acid, and phosphorylated polyaspartic acid.

[0130] Preferably, the structural unit of the phosphorylated polyglutamic acid PGA-P is as shown in Formula II:

[0131]

[0132] Wherein, in formula II, n2 is an integer of 100-2000;

[0133] Each Y is independently -OH, -OOP(OH)2, -NH(CH2) t OOP(OH)2 or -NH(CH2) t C(OH)(H2PO3)2, and each structural unit contains an average of 0.5-1 -OOP(OH)2, -NH(CH2) t OOP(OH)2 or -NH(CH2) t C(OH)(H2PO3)2; wherein t is 1-4.

[0134] Preferably, the second polymer has one or more of the following characteristics:

[0135] (a) a number average molecular weight of 10-1000 kDa, preferably 10-300 kDa;

[0136] (b) the molecular weight distribution coefficient is 1.0 to 2.0, preferably 1.0 to 1.5;

[0137] (c) In one structural unit, an average of at least 0.3 -OOP(OH)2, -NH(CH2)tOOP(OH)2 or -NH(CH2)tC(OH)(H2PO3)2 is contained, and preferably at least 0.5 -OOP(OH)2, -NH(CH2)tOOP(OH)2 or -NH(CH2)tC(OH)(H2PO3)2 is contained; wherein t is 1-4.

[0138] Preferably, in one structural unit, at least 0.7 -OOP(OH)2, -NH(CH2) t OOP(OH)2 or -NH(CH2) t C(OH)(H2PO3)2; wherein t is 1-4.

[0139] In a preferred embodiment of the present invention, the mass ratio of the first polymer to the second polymer in the organic component is 2:1-1:3.

[0140] Preferably, the mass ratio of the first polymer to the second polymer in the organic component is 1.5:1-1:3.

[0141] In a preferred embodiment of the present invention, the calcium phosphate salt and its derivatives are selected from one or a mixture of two or more of hydroxyapatite, tetracalcium phosphate, tricalcium phosphate, octacalcium phosphate and monocalcium phosphate.

[0142] In a preferred embodiment of the present invention, the mass ratio of the organic component to the inorganic component is 1:1-4:1.

[0143] Preferably, the mass ratio of the organic component to the inorganic component is 1:1-3:1, more preferably 1:1-2:1.

[0144] Preferably, the injectable bone adhesive has one or more of the following features:

[0145] (1) High mechanical strength, compression modulus reaches 600-1200 kPa, preferably 800-1000 kPa, compression strength reaches 400-700 kPa, more preferably 600-700 kPa;

[0146] (2) Excellent elasticity and toughness, the material toughness reaches 0.1-0.2MJ·m -3 , and the better one is 0.13-0.17MJ·m -3 ;

[0147] (3) Good injectability, gelation time is 0.3-1min;

[0148] (4) It can be injected in situ into the gaps between bone fragments, solidify quickly and adhere strongly to bone tissue.

[0149] The biocompatible bone adhesive of the present invention has good injectability and suitable curing time, has excellent topology, can be highly fitted with bone fragments of complex shapes in comminuted fractures, is conducive to the improvement of adhesion strength and the regulation of osteogenesis environment, has excellent bone adhesion strength and good mechanical properties, ensures stable fixation of bone fragments in fracture repair; at the same time, it has a certain osteogenesis ability and promotes fracture healing. The bone adhesive of the present invention is a material for bonding bone fragments in fracture treatment with clinical application prospects and value.

[0150] Compared with the prior art, the present invention has the following beneficial effects:

[0151] 1) The bone adhesive of the present invention has excellent mechanical properties and bonding strength;

[0152] 2) The bone adhesive of the present invention has good toughness and fatigue resistance;

[0153] 3) The bone adhesive of the present invention can be cured in situ by injection into the desired part, and the curing time can be adjusted between 0.3-1 min;

[0154] 4) The bone adhesive of the present invention has excellent topology and can be highly consistent with the shape of bone fragments;

[0155] 5) The rheological properties, injection properties, mechanical properties and cell behavior of the bone adhesive of the present invention can be regulated and optimized by changing the content of its components;

[0156] 6) The bone adhesive of the present invention is biodegradable, and the degradation time matches the new bone ingrowth;

[0157] 7) The bone adhesive of the present invention has the performance of promoting bone regeneration and new bone ingrowth;

[0158] 8) The minimally invasive properties of the bone adhesive described in the present invention give it a promising prospect in clinical application.

[0159] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.

[0160] Example 1. Preparation of bone tissue adhesive hydrogel

[0161] 1.1 Synthesis and purification of PEGS-NH2

[0162] 1.1.1 N-(tert-butyloxycarbonyl) aminoacetic acid modified PEGS

[0163] (a1) 1.95 g of sebacic acid (0.01 mol) and 20 g (0.07 mol) of tetrabutylammonium hydroxide (25 wt% aqueous solution) were added to 100 mL of 95% ethanol, stirred at 55° C. for 30 min, then the ethanol was removed by rotary evaporation at 40° C., and finally lyophilized to obtain the product di(tetrabutylammonium hydroxide) sebacic acid ester (TBAS);

[0164] (b1) Under nitrogen atmosphere, 20.23 g of sebacic acid (0.1 mol), 50.00 g of polyethylene glycol diglycidyl ether and 0.41 g of the product TBAS of step (a1) were weighed, and the above raw materials were mixed and dissolved in 180 mL of anhydrous N,N-dimethylformamide, and stirred at 100° C. for 72 h;

[0165] (c1) dialysis purification of the product of step (b1) to obtain purified linear polyester PEGS;

[0166] (d1) Under nitrogen atmosphere, weigh 10.53 g of the linear polyester PEGS obtained in step (c1), 6.31 g of N-(tert-butyloxycarbonyl)aminoacetic acid, 7.57 g of N,N'-diisopropylcarbodiimide (0.06 mol) and 0.18 g of 4-dimethylaminopyridine (0.001 mol), blend and dissolve the above raw materials in 150 mL of anhydrous dichloromethane, and stir at room temperature for 24 h;

[0167] (e1) The product obtained in step (d1) is filtered and concentrated, and the tert-butyloxycarbonyl group is removed using trifluoroacetic acid, and then the product is dialyzed and purified using a dialysis bag with a molecular weight cutoff of 3500 Da to obtain amino polyester PEGS (PEGS-NH2).

[0168] The obtained amino polyester PEGS is light yellow, transparent and viscous, with a molecular weight of 8000-18000Da, a molecular weight distribution coefficient of 1.20-1.50, and an actual amino grafting rate of 90-95%. The nuclear magnetic resonance hydrogen spectrum and Fourier transform infrared spectrum are shown in Figure 2 As shown in A and B.

[0169] To further demonstrate the diversity and feasibility of the synthesis of amino PEGS, this experiment used N-(tert-butoxycarbonyl)aminovaleric acid, hydrazideacetic acid and guanidinoacetic acid to replace N-(tert-butoxycarbonyl)aminoacetic acid in the above method, and PEGS was successfully amino-modified.

[0170] 1.1.2 N-(tert-butyloxycarbonyl)aminovaleric acid modified PEGS

[0171] In this experiment, the preparation method is the same as 1.1.1, except that PEGS was aminated using N-(tert-butoxycarbonyl)aminovaleric acid instead of N-(tert-butoxycarbonyl)aminoacetic acid. The results showed that the obtained amino polyester PEGS was yellow, transparent and viscous, with a molecular weight of 8000-20000Da, a molecular weight distribution coefficient of 1.2-1.5, and an actual amino grafting rate of 85-95%.

[0172] 1.2 Synthesis and purification of PGA-P

[0173] 1.2.1 O-phosphoethanolamine modified PGA

[0174] (a2) dissolving polyglutamic acid, O-phosphoethanolamine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) in ultrapure water at a molar ratio of 1:1:1.5:1.5, and stirring at room temperature for 24 hours to obtain a colorless transparent liquid;

[0175] (b2) The solution obtained in step (a2) is dialyzed and lyophilized to obtain phosphorylated polyglutamic acid (PGA-P).

[0176] The phosphorylated polyglutamic acid obtained is white cotton-like, with a molecular weight of 300-400 kDa, a molecular weight distribution coefficient of 1.20-1.50, and an actual phosphoric acid group grafting rate of 70-80%. The nuclear magnetic resonance hydrogen spectrum, phosphorus spectrum and Fourier transform infrared spectrum are shown in Figure 3 As shown in A, B, and C.

[0177] To further demonstrate the diversity and feasibility of phosphorylated polyglutamate synthesis, this experiment used pamidronate and alendronate to replace O-phosphoethanolamine in the above method, and successfully phosphorylated PGA.

[0178] 1.2.2 Pamidronate-modified PGA

[0179] In this experiment, the synthesis steps are the same as 1.2.1, except that pamidronic acid is used instead of O-phosphoethanolamine in the above method.

[0180] The phosphorylated polyglutamic acid obtained is in the form of white cotton wool, has a molecular weight of 300-500 kDa, a molecular weight distribution coefficient of 1.2-1.5, and an actual phosphoric acid group grafting rate of 50-70%.

[0181] 1.3 Preparation of injectable bone adhesive

[0182] The specific formula is shown in the following table. The preparation method of the tissue adhesive hydrogel specifically includes the following steps:

[0183] (a3) Dissolve PEGS-NH2 and PGA-P in ultrapure water and stir well.

[0184] (b3) adding tetracalcium phosphate to the solution obtained in step (a3) ​​and stirring uniformly.

[0185] (c3) Add EDC / NHS aqueous solution to the solution obtained in step (b3), stir quickly and evenly to form a gel for injection. Figure 1 Shown is a schematic diagram of the structure and application of the bone adhesive material of the present invention.

[0186] Table 1 Ratio of raw materials for preparing injectable bone adhesive with different cross-linking degrees

[0187]

[0188] Table 2 Different organic and inorganic ratios

[0189]

[0190] Table 3 Different proportions of organic ingredients

[0191]

[0192]

[0193] Table 4: Mechanism exploration (chemical and physical crosslinking)

[0194]

[0195] Through electrostatic action, the bone adhesive precursor solution is a flowable, stable, and uniformly dispersed complex. Under the action of the crosslinking agent EDC / NHS, chemical crosslinking is formed between PEGS-NH2 and PGA-P. In this embodiment, five bone adhesives with different crosslinking degrees (as shown in Table 1) are prepared by adjusting the molar ratio of EDC / NHS to the amino group in the amino PEGS (0-70%). Table 2 shows the bone adhesives prepared under different organic and inorganic ratios, and Table 3 shows the adhesives prepared under different organic component ratios. In order to explore the mechanism of the adhesive, a study on the crosslinking mechanism was conducted as shown in Table 4. The content of 0 indicates a bone adhesive hydrogel that is chemically crosslinked without adding a crosslinking agent.

[0196] In order to further prove the variability of PGA, this experiment replaced PGA with polyaspartic acid, an amino acid that also has a side carboxyl group, and prepared bone adhesive with the same ratio. The experimental results showed that the bone adhesive prepared by phosphorylated polyaspartic acid and the hydrogel prepared by PGA-P had similar physical and chemical properties.

[0197] 1.4 Preparation of bone adhesive - polyaspartic acid

[0198] In this experiment, aspartic acid was phosphorylated and the synthesis process was the same as 1.2, except that PGA was replaced with an amino acid that also has a side carboxyl group, polyaspartic acid.

[0199] The preparation process of bone adhesive is the same as 1.3, except that PGA-P is replaced with phosphorylated polyaspartic acid to prepare an adhesive with similar physical and chemical properties to the hydrogel prepared with PGA-P: the bone adhesive precursor solution is a flowable, stable, and evenly dispersed complex, and the precursor solution solidifies rapidly under the action of the cross-linking agent EDC / NHS.

[0200] Example 2. Rheological Characterization of Injectable Bone Adhesive

[0201] In order to evaluate the injectability of the mixture used to prepare the bone adhesive, the present embodiment uses a rotational rheometer to investigate the changes in the storage modulus and loss modulus during the curing process of the adhesive and the curing time. The test temperature is 37°C, the frequency is fixed at 10 Hz, the strain is fixed at 5%, and the test time is 3 min. The data is recorded to obtain the change curve of the storage modulus (G') and the loss modulus (G") versus time during the curing process of the injectable bone adhesive, and the curing time of the bone adhesive is obtained by analysis and calculation.

[0202] Figure 4 This indicates that the injectable bone adhesive has good injectability and topological properties and can be prepared into complex shapes. Figure 5 The results showed that the gelation time of all groups of hydrogels was 0.3-1min, and they had good injectability.

[0203] Example 3. Characterization of the bone adhesion properties of injectable bone adhesive

[0204] In order to evaluate the adhesion of injectable bone adhesive to bone, this example uses pig femur as a model bone tissue. According to the lap-shear model, the bone adhesive is injected into the surface of two pieces of bone and tested using a universal tensile testing machine at 2 mm / min. -1 The bonding performance test was carried out at a tensile rate of 1.

[0205] The results are as follows Figure 6-7 As shown. Figure 6 It can be seen that by controlling the variables, the bone adhesion strength first increases and then decreases with the increase of calcium phosphate salt component and the increase of the second polymer, and a peak value appears. In this way, the material component with the best adhesion strength is screened out, that is, the optimal ratio between the first polymer, the second polymer and calcium phosphate salt.

[0206] from Figure 7As can be seen from B in the figure, the bone adhesive has excellent bone adhesion strength comparable to that of 502 glue, meeting the requirements for the adhesion and fixation of bone fragments in fracture repair surgery. The bone adhesion strength increases first and then decreases with the increase of cross-linking degree, and a peak value appears.

[0207] Example 4. Characterization of the compression properties of injectable bone cement

[0208] In order to evaluate the compression properties of injectable bone adhesive, a universal tensile testing machine was used to perform compression tests on bone adhesive. The compression speed was fixed at 2 mm / min. -1 , record data and draw compression curves, analyze and evaluate the compression modulus and compression strength of bone adhesive.

[0209] The results are as follows Figure 8 As shown in . Figure 8 As can be seen from B in the figure, the compression modulus of the bone adhesive can reach 600-1200 kPa, indicating that the bone adhesive has a high modulus, ensuring that a smaller displacement is produced under possible stress conditions in actual applications. The compression modulus increases with the increase in crosslinking degree. Figure 8 As can be seen from C in the figure, the compression strength of bone adhesive can reach 400-700 kPa, which means that bone adhesive has high compression strength and is not easy to be damaged. The compression strength increases first and then decreases with the increase of cross-linking degree, and a peak value appears.

[0210] Example 5. Characterization of Cyclic Loading Compression Performance of Injectable Bone Adhesive

[0211] In order to evaluate the energy dissipation and fatigue resistance of injectable bone adhesive, this study used a universal tensile testing machine to perform a cyclic loading compression test on the bone adhesive. The compression speed was fixed at 2 mm min -1 , compress to 30% strain and then release the stress to 0 MPa, cycle 10 times, record the data and draw the cyclic loading and compression curve, analyze and evaluate the energy dissipation efficiency and anti-fatigue performance of the bone adhesive.

[0212] The results are as follows Fig. 9 As shown in . Fig. 9 As can be seen from B in the figure, bone adhesive has certain energy dissipation characteristics, which ensures that energy dissipation can be generated when impacted in actual applications, reducing damage to the material itself. The energy dissipation efficiency increases first and then decreases with the increase of cross-linking degree, and a peak value appears.

[0213] Example 6. Mechanism of injectable bone adhesive

[0214] In order to evaluate the effects of chemical crosslinking and physical crosslinking of injectable bone adhesive on the material properties, each group of adhesives were immersed in ultrapure water for 24 hours after molding, and then the excess water was absorbed to investigate the swelling and compression properties.

[0215] The results are as follows Fig.10 As shown. Fig.10 From A and B, it can be seen that the non-loaded calcium phosphate salt will absorb more water and swell, while the loaded calcium phosphate salt effectively controls the swelling through the electrostatic effect of the negatively charged groups on calcium ions. In addition, the swelling of the phosphorylated PGA is smaller than that of the unmodified PGA, indicating that the electrostatic effect of the phosphoric acid group on calcium ions is stronger than that of the carboxyl group. Fig.10 As can be seen from C and D, the compressive strength and modulus of the injectable bone adhesive were greatly improved after loading with calcium phosphate salts, and the compressive properties were further improved after phosphorylation modification of PGA, which also confirmed that the electrostatic effect of phosphate groups on calcium ions was stronger than that of carboxyl groups, which enhanced the cohesive properties of the material itself. Although the NPC 0 group without chemical cross-linking had a small swelling, its compressive properties were very weak and could not be measured by instruments.

[0216] Example 7. Characterization of Cytocompatibility of Injectable Bone Cement

[0217] In order to evaluate the cytocompatibility of injectable bone adhesive, this experiment used bone marrow mesenchymal stem cells (BMSCs) co-cultured with adhesive to investigate its cytotoxicity at 1d, 4d, and 7d. The specific scheme is to first prepare the bone adhesive in situ at the bottom of a 96-well plate and sterilize it, then 3 The density of cells was inoculated on the surface of the bone adhesive, and the CCK-8 kit was used to evaluate the cell viability at 1d, 4d, and 7d. As shown in the figure, the NPC group is NPC6, that is, NPC6 is selected as the best group of materials, and subsequent experimental controls such as cells and animals are performed. The CA group is a cyanoacrylate tissue adhesive commonly used in clinical practice, which is generally considered to have high bonding strength, but has problems such as cytotoxicity and difficulty in degradation.

[0218] from Fig.11 It can be seen that all groups of bone adhesives had no obvious toxicity to the cells compared with the blank well plate control (TCP) at 1d, 4d, and 7d of co-culture with BMSCs cells, indicating that the injectable bone adhesive of the present invention has good cell compatibility.

[0219] Example 8. Characterization of osteogenic properties of injectable bone adhesive

[0220] In order to evaluate the in vitro osteogenic performance of injectable bone adhesive, this study selected NP and NPC6 as the material group, and used bone marrow mesenchymal stem cells (BMSCs) co-cultured with adhesive to investigate their alkaline phosphatase (ALP) activity and mineralization at 2W. The specific plan was to set up groups and prepare samples according to the above method. Bone marrow mesenchymal stem cells (BMSCs) were cultured at 5×10 3 The cells were seeded into 24-well plates at a density of 1 / well and incubated in a commercial osteogenic induction medium (RAXMX-90021, ) (α-MEM containing 2% FBS, 0.05 mM L-ascorbic acid, 100 mM β-glycerophosphate and 100 mM dexamethasone). After culturing for 2 weeks, the medium was removed, the cells were washed twice with PBS, stained with BCIP / NBT alkaline phosphatase colorimetric kit, and photographed.

[0221] The results are as follows Fig.12 As shown, the injectable bone adhesive of the present invention has good in vitro osteogenic performance.

[0222] Example 9. In vivo fracture repair characterization of injectable bone adhesive

[0223] To evaluate the in vivo fracture repair performance of injectable bone adhesive, NPC6 was used as the material group and rat tibia was used as the animal model. A reciprocating saw was used to cut the rat tibia along 1 / 3 of the thickness to form 1 cm long bone fragments, and bone adhesive was injected to bond the fragments. After the gel was formed, the wounds were sutured and the rats were killed and observed after 4 and 8 weeks, respectively.

[0224] The results are as follows Fig.13 As shown, the injectable bone adhesive of the present invention has good in vivo fracture adhesion and repair performance, ensuring that rats remain adhered 4 weeks after bone adhesive adhesion and repair, and the overall repair is good after 8 weeks, with no obvious interface between the bone fragments and the tibia body.

[0225] discuss

[0226] In the present invention, the inventors combined the characteristics of bone tissue and the clinical needs of fracture repair surgery, and after extensive and in-depth research, developed for the first time an injectable bone adhesive with high mechanical and adhesion strength that can promote new bone regeneration for the bonding of bone fragments in fracture repair surgery, targeting the shortcomings of existing bone adhesives such as poor mechanical and adhesion strength and poor degradation performance that are not conducive to new bone formation and fracture healing.

[0227] The present invention uses amino polyhydroxy polyethylene glycol polysebacic acid glyceride (PEGS-NH2) and phosphorylated polyglutamic acid (PGA-P) as the main matrix materials, adds tetracalcium phosphate (TTCP), and forms a bone adhesive precursor solution with a certain viscosity through the electrostatic action of phosphate groups and carboxyl groups on calcium ions. Finally, under the action of cross-linking agent EDC / NHS, the above bone adhesive precursor solution can be mixed and injected into the surface of bone tissue, quickly solidifies in situ and forms a strong bonding effect. In addition, the hydrogel also has excellent mechanical properties and the performance of promoting osteogenesis.

[0228] Specifically, the injectable bone adhesive of the present invention has a double cross-linked network inside, including PEGS-NH2 and PGA-P in the organic component forming covalent chemical cross-linking under the action of a cross-linking agent, and electrostatic physical cross-linking spontaneously formed with PGA-P and inorganic calcium phosphate. At the same time, the injectable bone adhesive of the present invention can form a variety of bonds with the surface of bone tissue, including stable amide covalent bonds, electrostatic chelation of calcium ions by phosphate groups and carboxyl groups, and hydrogen bonding. The introduction of the calcium phosphate component not only improves the mechanical properties of the bone adhesive, but also enhances its osteoconductivity, promotes new bone regeneration, and is beneficial to fracture recovery. In addition, it has good injectability, can be injected into the surface of bone tissue to solidify into gel in situ and form a strong adhesion effect.

[0229] In summary, the injectable bone adhesive of the present invention has a suitable curing time, good injection performance, excellent mechanical and adhesion properties, good fatigue resistance and a certain osteogenesis effect. Therefore, the injectable bone adhesive of the present invention can be used for bonding bone fragments in repair surgery for fractures, especially comminuted fractures, and promote bone regeneration, and is an injectable bone adhesive material with clinical application prospects.

[0230] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. An injectable bone adhesive, It is characterized in that The injectable bone adhesive comprises the following components: (c1) an organic component, the organic component comprising: a first polymer and a second polymer; (c2) Inorganic components, which include calcium phosphate salts and their derivatives.

2. The injectable bone cement according to claim 1, It is characterized in that The first polymer is a modified polyester polymer, including: amino polyhydroxy polyethylene glycol polysebacic acid glycerol PEGS-NH 2 , amino polysebacic acid glyceryl ester, amino polyethylene glycol polysebacic acid glyceryl ester.

3. The injectable bone cement according to claim 1, It is characterized in that The second polymer is a polyamino acid or a phosphorylated modified product thereof, including: polyglutamic acid, phosphorylated polyglutamic acid PGA-P, polyaspartic acid, and phosphorylated polyaspartic acid.

4. The injectable bone cement according to claim 1, It is characterized in that The mass ratio of the first polymer to the second polymer in the organic component is 2:1-1:

3.

5. The injectable bone cement according to claim 1, It is characterized in that The calcium phosphate salt and its derivatives are selected from one or a mixture of two or more of hydroxyapatite, tetracalcium phosphate, tricalcium phosphate, octacalcium phosphate and monocalcium phosphate.

6. The injectable bone cement according to claim 1, It is characterized in that The mass ratio of the organic component to the inorganic component is 1:1-4:

1.

7. A method for preparing the injectable bone adhesive as claimed in claim 1, It is characterized in that The method comprises the steps of: (a) providing a bone adhesive precursor solution, wherein the bone adhesive precursor solution comprises a first polymer, a second polymer, and a calcium phosphate salt; (b) providing a cross-linking agent solution, wherein the cross-linking agent comprises 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS); (c) mixing the bone adhesive precursor solution with the cross-linking agent solution to obtain the injectable bone adhesive, The preparation of the bone adhesive precursor solution comprises the following steps: (a1) dissolving the first polymer and the second polymer in a solvent to obtain a mixed solution; (a2) adding calcium phosphate salt to the mixed solution, and mixing to obtain the bone adhesive precursor solution.

8. The method according to claim 7, It is characterized in that The cross-linking agent in step (b) is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) for catalyzing the formation of amide bonds.

9. The injectable bone cement according to claim 7, It is characterized in that In step (b), the molar ratio of EDC to NHS in the cross-linking agent is 0.5 to 2:1, and the molar ratio of EDC to the amino group in the first polymer is 0.5 to 1:

1.

10. A kit for forming the injectable bone adhesive of claim 1, the kit comprising: the bone adhesive precursor solution of claim 1 and a cross-linking agent solution.

11. Use of the injectable bone adhesive according to claim 1, It is characterized in that For any one or two or more of the following applications: (i) preparing bone fragment bonding materials for fracture repair surgery; (ii) preparing bone tissue defect filling materials; (iii) preparing materials for guiding tissue regeneration; (iv) Preparation of medical cosmetic materials.

Citation Information

Cited By

  • Carbon dot / calcium phosphate composite bone glue with high shear strength and active oxygen scavenging capacity and preparation method thereof

    CN121422278A